CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 44 enrolled
Drug / intervention
MoodElite T-4003-1 +2 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05318456
NCT05318456Phase 2Completed
CompareCT.gov

A Randomized, Triple-blind, Placebo-controlled, Parallel Clinical Trial to Investigate the Safety and Efficacy of MoodElite T-4003-1 on Improving Mood in a Healthy Adult Population With Mild to Moderate Depressive Symptoms Not Eligible for Therapeutic Intervention

Chenland Nutritionals Inc.·interventional·Posted Apr 8, 2022·Updated Mar 22, 2023

In Brief

A Phase 2 clinical trial evaluating MoodElite T-4003-1, Comparator, and 1 other intervention for Mood. Completed, enrolled 44 participants across 1 site.

Detailed Summary

The objective of this study is to investigate the efficacy and safety of MoodElite T-4003-1 on improving mood in a healthy adult population with mild to moderate depressive symptoms not eligible for therapeutic intervention.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMood
CountriesCanada
CollaboratorsKGK Science Inc.

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedApr 8, 2022
Enrollment StartMar 24, 2022
Primary CompletionJan 19, 2023
Study CompletionMar 20, 2023
TodayJul 1, 2026
Enrollment to primary: 10 monthsPosted 4.2 years ago

Interventions

MoodElite T-4003-1dietary

Participants will be instructed to take two capsules of MoodElite T-4003-1 once daily with water, after dinner without food for 42 days.

Comparatordietary

Participants will be instructed to take two capsules of comparator once daily with water, after dinner without food for 42 days.

Placeboother

Participants will be instructed to take two capsules of placebo once daily with water, after dinner without food for 42 days.